Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Pediatr Res. 2013 May 22;74(2):111–120. doi: 10.1038/pr.2013.80

Table 2.

Treatment effects in the left ventricle

	Female			Male

	Nc	Gr	Hx	Nc	Gr	Hx

Mass (mg g body ⁻¹)	3.4±0.08	3.3±0.06	7.2±0.71^*^§	3.4±0.08	3.3±0.04	8.8±1.5^*^§
Protein Content (mg)	174±5.8	112±2.0^*	230±18^*^§	184±7.4	124±3.6^*	196±26^§
Myofibrillar Protein (mg)	13.6±0.56	8.13±0.25^*	16.19±1.4^§	14.6±0.75	9.39±0.27^*	14.91±1.9^§
DNA Content (μg)	471±19	365±17^*	611±36^*^§	522±8	394±12^*	506±39^§
RNA Conc. (mg g⁻¹)	2.5±0.07	2.5±0.05	2.5±0.05	2.3±0.07	2.4±0.08	2.4±0.08
α-MHC (% total)	97.8±0.6	95.8±1.5	83.2±2.9^*^§	97.1±0.8	95.1±1.1	77.3±5.9^*^§
β-MHC (% total)	2.1±0.6	4.3±1.5	16.8±2.9^*^§	2.9±0.8	4.9±1.1	22.7±5.8^*^§
HIF1α mRNA (AU)	0.90±0.03	0.92 +0.03	0.76±0.03^*^§	0.95±0.02	0.93±0.03	0.87±0.07
HYOU1 mRNA (AU)	0.93±0.05	0.98±0.04	0.68±0.05^*^§	0.85±0.06	0.95±0.04	0.62±0.07^*^§
VEGF mRNA (AU)	0.87±0.04	0.86±0.02	0.69±0.02^*^§	1.02±0.03	1.01±0.04	1.00±0.12
Myostatin mRNA mg⁻¹	88.5±12.5	116.1±10.1	39.3±5.9^*^§	55.8±10.8	75.6±3.5	25.0±6.5^*^§
IGFBP5 mRNA mg⁻¹	57.2±5.9	58.7±4.3	66.3±13.0	41.3±6.4	41.2±5.4	19.9±4.2^*^§
miR1 (AU)	1.01±0.06	1.04±0.05	0.98 ±0.04	1.13±0.06	1.09±0.07	0.83±0.08^*^§

n ≥ 7,

^*

P<0.05 vs. Nc;

^§

P<0.05 vs. Gr.;

Conc.: concentration; AU: Arbitrary units.